The Next Wave of 17-Year Cicadas Is About to Party, Scream, and Die
Brood XIV will emerge this summer to overwhelm predators, shake up ecosystems, and terrify everyone with eardrums.
A special brood of cicadas—an ancient lineage of the periodical insects—is set to burst from the soil this May and June, covering more of the United States than any other 17-year brood.
These bugs—collectively known as Brood XIV—have been biding their time underground since the last Bush administration, biding their time and counting the years go by. Now they're back with two goals: Get loud and get laid.
This isn't just any swarm. Brood XIV is considered the original brood, from which all other 17-year cicada broods split off, according to YaleEnvironment360. This is the motherlode of massive, crunchy, droning insects.
For a few wild weeks to come, the skies will fill with their raspy mating calls, as the insects rise up simultaneously. The synchronized emergence isn't just for flair. It's a numbers game: By surfacing in the billions, cicadas overwhelm their predators—birds, squirrels, snakes, you name it—who are so sated by the plenty that the cicadas' arrival sends waves through the food chain.
When cicadas emerge, populations of cuckoos, blue jays, and some woodpecker species swell. But not all the effects are good: Because the birds are busy eating cicadas, caterpillar populations can go unchecked, allowing those bugs to damage oak trees to a greater degree.
Most of the insects will get eaten, but enough will survive to keep the brood going. Once the survivors lay their eggs—their purpose fulfilled—they die. The brood's tiny offspring disappear underground for another 17 years, from which they will rise again in 2041.
The cicadas are expected to appear as far west as Kansas, as far north as Wisconsin and Michigan, down through the Mississippi Delta to New Orleans, and along much of the East Coast from Georgia and South Carolina up to Connecticut. You can review a detailed map of broods, including where they historically have emerged and are expected to emerge again, at this University of Connecticut site.
And as with everything else these days, climate change could be messing with the cicada clock. A Japanese study found that warming temperatures are pushing some cicadas to emerge earlier in the year. Over time, hotter conditions might even shrink their 17-year underground snooze.
But those are longer term forecasts, and Brood XIV's timing is imminent. In the next weeks, if you hear droning and you're not near a construction site, there's no need to panic: It's just billions of bugs on a once-in-a-generation bender.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
12 minutes ago
- Associated Press
Dilly Dally the sea turtle returns to the ocean after flipper amputation
JUNO BEACH, Fla. (AP) — An adolescent loggerhead sea turtle named Dilly Dally crawled into the Atlantic Ocean Wednesday morning, months after having a front flipper amputated at a Florida turtle hospital. The turtle was brought to Loggerhead Marinelife Center in January suffering from predator wounds to the front flipper. The veterinary crew at the Juno Beach facility assisted in Dilly Dally's rehabilitation and care. 'Every time we can release a turtle back into the wild is special and not just for us but for all the interns and volunteers and everyone that puts an effort to getting these turtles back out there. It's always a really special day,' said Marika Weber, a veterinary technician at the center. Stormy weather on Wednesday almost caused Dilly Dally's release to be postponed. But they packed the turtle up and drove the short distance to the beach. A crowd of beachgoers cheered as the turtle made its way to the ocean. A satellite tracking device attached to Dilly Dally's shell will allow the center and the public to follow her journey. The center partnered with the Smithsonian to get the satellite tag, which was attached on Tuesday. 'So now Dilly Dally has an active live satellite tag on her and we can get real-time data on where she goes, which is really exciting because we don't really know what happens to our three flipper turtles once you release them, Weber said. 'Now we know if their migration or foraging patterns change and it'll be really helpful to see what happens to these patients.' All sea turtles are endangered or threatened species. 'So every sea turtle that we can save and get back out there is the win for the species.' Follow Dilly Dally's journey at Marinelife Turtle Tracker. ____ Frisaro reported from Fort Lauderdale, Florida.
Gizmodo
23 minutes ago
- Gizmodo
New Russian Satellite Appears to Be Stalking U.S. Satellite in Orbit
A recently launched Russian satellite is getting uncomfortably cozy with a U.S. reconnaissance satellite, leading Space Command to worry that it's part of an anti-satellite weapon being deployed to orbit. Cosmos 2588 launched on May 23 to a near-circular orbit, placing it eerily close to a U.S. reconnaissance satellite, USA 338. The move prompted suspicion that it's an attempt by Russia to deliberately stalk the U.S. government satellite. This isn't the first time Russia has deployed a sneaky satellite to trail behind and allegedly observe another satellite in orbit, but this time it may be connected to Russia's controversial anti-satellite program. 'U.S. Space Command can confirm Russia's recent launch put a Russian satellite into an orbit near a U.S. government satellite,' a Space Command spokesperson is quoted as saying to Breaking Defense. 'Russia continues to research, develop, test, and deploy a suite of counter space systems that threaten the safety and the stability of the domain, so consistent with all on-orbit objects, USSPACECOM will continue to monitor for concerning behavior or activity related to this launch.' Slingshot Aerospace reports that the alleged spy satellite, Cosmos 2588, is a NIVELIR military inspection satellite likely carrying a kinetic weapon onboard. Its alignment with USA 338 'strongly suggests COSMOS 2588 may be actively monitoring or 'chasing' it,' the satellite tracking company wrote in a statement. Slingshot Aerospace has been tracking the two satellites, revealing that Cosmos 2588 is orbiting at a slightly higher altitude and that the two objects will have a close flyby of one another roughly every four days. The two satellites come as close as 62 miles (100 kilometers) from one another, Marco Langbroek, an astronomer and expert on space situational awareness at the Delft University of Technology in the Netherlands, wrote on X. Not much else is known about USA 338 as it doesn't have publicly available orbital data, but it is believed to be a part of the National Reconnaissance Office's KH-series electro-optical surveillance network, known as the Crystal constellation, according to Interesting Engineering. This isn't the first time Russia has allegedly deployed a satellite for such a purpose. In April 2023, a Russian satellite appeared to be closely trailing a classified U.S. military satellite, and Russia's Kosmos 2558, launched in August 2022, was deployed into the same orbital plane as a U.S. military satellite, dubbed USA 326. In 2020, another Russian satellite, Kosmos 2542, stalked USA 245, an electro-optical spy satellite in low Earth orbit. The U.S. isn't completely innocent either. In June 2017, classified U.S. military satellite USA 276 snuck up on the International Space Station at a close distance of about 4 miles (6.4 kilometers). Earlier in 1998, hobbyists discovered a U.S. satellite that was believed to have been used for space spying purposes as well. Russia's satellites, however, are believed to be part of the country's efforts to develop an anti-satellite weapon designed to destroy other objects in space. In November 2021, Russia destroyed a defunct Soviet-era satellite in low Earth orbit, producing thousands of pieces of orbital debris. The test prompted the United Nations to draft a resolution against tests of anti-satellite (ASAT) missile systems, which was led by the Biden administration after the U.S. adopted a self-imposed ban on ASAT tests. A total of 155 countries voted in favor of the resolution, while nine voted against it, including Russia, China, Cuba, Syria, and Iran. 'This is the fourth time in five years that they launch a satellite into a coplanar orbit with a US optical reconnaissance satellite,' Langbroek wrote on X. 'So no, not mere coincidence but deliberate.'
Medscape
23 minutes ago
- Medscape
Fact or Fiction: Ovarian Cancer and Drug Resistance
In ovarian cancer, the emergence of drug resistance has been shown to limit the durability of therapeutic treatment benefit and contribute substantially to ovarian cancer's high mortality rate. Factors such as treatment-free intervals and tumor microevolution may allow for re-sensitization to platinum agents in select patients. In addition to tumor biology, the tumor microenvironment plays a pivotal role in therapeutic resistance. Targeted therapies, once heralded as a solution to chemotherapy resistance, have been shown to face similar obstacles. Drug resistance in ovarian cancer management is an ongoing field of study as clinicians look to limit its impact improve outcomes. Platinum resistance in ovarian cancer is not always permanent. While many patients relapse with tumors less responsive to platinum-based chemotherapy, resistance can be dynamic. Mechanisms such as epigenetic alterations, modulation of DNA damage response, and temporary activation of drug efflux pumps may contribute to reversible resistance. Importantly, a subset of patients initially labeled as platinum-resistant may benefit from platinum rechallenge after a treatment-free interval, particularly if newer maintenance strategies or resensitizing agents are used. This has led to the concept of a "platinum-free interval" to help guide re-treatment. Understanding these nuances is crucial for tailoring treatment strategies and optimizing outcomes. Learn more about medications used in ovarian cancer. While HRD — often due to BRCA1/2 mutations — initially predicts strong sensitivity to DNA-damaging therapies like platinum agents and PARP inhibitors, resistance commonly emerges over time. A key mechanism is the restoration of homologous recombination through secondary or "reversion" mutations in HR pathway genes. These mutations enable tumor cells to resume high-fidelity DNA repair, diminishing the cytotoxic effects of therapy. Additionally, tumors may activate compensatory pathways such as non-homologous end joining or increase drug efflux activity. This resistance may not be detectable at diagnosis and can evolve under therapeutic pressure. Consequently, current research emphasizes longitudinal molecular monitoring to capture evolving resistance mechanisms. Clinically, this underscores the need for re-biopsy or circulating tumor DNA analysis to reassess HR status in recurrent disease, which may influence therapy selection. Learn more about the importance of biopsy in ovarian cancer. Tumor heterogeneity — both genetic and phenotypic — plays a central role in drug resistance and further complications treatment outcomes. Ovarian tumors often consist of diverse subclonal populations, some of which may possess innate resistance traits. Within a single ovarian tumor, multiple subclonal populations may coexist, each with distinct characteristics and sensitivity profiles. When systemic therapy is applied, sensitive clones are eliminated, but resistant ones may persist and expand. Single-cell and spatial transcriptomics studies have mapped how this clonal evolution occurs, revealing that treatment can select for resistant subpopulations not evident at baseline. Heterogeneity also affects the tumor microenvironment and immune response, further complicating therapeutic strategies. Clinically, this variability can manifest as mixed responses, where some lesions regress while others progress. Addressing heterogeneity remains a major challenge and has sparked interest in combination therapies and adaptive trial designs. Personalized treatment strategies based on real-time tumor profiling are likely to improve outcomes by accounting for this complexity. Learn more about ovarian cancer guidelines. Targeted therapies are susceptible to various resistance mechanisms, many of which overlap with those seen in chemotherapy. For example, resistance to PARP inhibitors, widely used in HRD-positive ovarian cancers, can arise from secondary mutations restoring DNA repair function or through enhanced drug efflux. Similarly, resistance to angiogenesis inhibitors may develop via upregulation of alternative pro-angiogenic pathways or changes in tumor vasculature that circumvent the need for VEGF signaling. Resistance is further complicated by factors such as epigenetic reprogramming and altered cell signaling networks. These findings have led to interest in combining targeted agents with immune checkpoint inhibitors, DNA repair modulators, or epigenetic therapies to overcome resistance. Future success with targeted therapy will likely depend on combination approaches informed by tumor genomics and adaptive resistance profiling. Learn more about risk assessment and genetic counseling in ovarian cancer. The tumor microenvironment (TME) is a key contributor to drug resistance in ovarian cancer. Immune cells such as regulatory T cells and tumor-associated macrophages (TAMs) create an immunosuppressive milieu that hinders effective therapy. Additionally, fibroblasts and extracellular matrix components can form physical barriers that limit drug penetration. Cytokines and growth factors secreted within the TME also modulate signaling pathways in tumor cells, promoting survival and resistance. Studies have shown that high TAM density is associated with poor response to both chemotherapy and immunotherapy, and interventions targeting the TME may help reverse resistance. This includes strategies like macrophage reprogramming, TME remodeling agents, and stromal-targeting therapies. Incorporating TME characteristics into clinical decision-making may help guide therapeutic combinations and predict response. Learn more about tumor biomarkers in ovarian cancer.
